Chemotherapy-induced Ovarian Failure And The Related Indices In Breast Cancer Patients

سال انتشار: 1385
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 861

متن کامل این مقاله منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل مقاله (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJP-1-3_003

تاریخ نمایه سازی: 5 آبان 1393

چکیده مقاله:

Background and Objective: It is well known that menstrual period and ovarian function are affected by chemotherapy. Although breast cancer is the most common cause of chemotherapy inwomen and ovarian hormones have very important direct and indirect effects on overall survival, disease-free survival, and life quality of patients, but few studies have addressed the frequency and related factors of ovarian failure in breast cancer patients after receiving conventional regimensof chemotherapy. Therefore, the risk of ovarian failure after conventional chemotherapy regimensfor breast cancer (with and without taxans) and the factors that influence ovarian function due to chemotherapy including patient’s age and type and dosage of drugs were investigated in thisstudy. Materials and Methods: The cross sectional protocol of this study was conducted on81 premenopausal breast cancer patients with regular menstruation that were candidates forchemotherapy and had not any history of prior hormonal therapy or chemotherapy. Alteration ofmenstrual cycles and ovarian function were evaluated by measuring blood levels of FSH and LH. Then, the role of patient’s age, type and dosage of drugs were analyzed on ovarian function. Results: Out of a total of 81 patients evaluated, 44 (54.3%) were found to suffer from ovarianfailure after chemotherapy. There was also no significant difference for the risk of ovarian failure between two major groups of chemotherapy regimens. In addition, the probability of ovarian failure increased after increasing the dosage of the drug. Meanwhile, patients over 40 years weremore sensitive to chemotherapy than younger ones. Conclusion: It is concluded that patient’s age is the most important factor determining the risk of chemical castration. In this respect, addition of taxans to conventional chemotherapy does not increase the risk of chemical castration.

کلیدواژه ها:

نویسندگان

Robab Anbiaee

Department of Radiotherapy and Oncology, Shaheed Beheshti University of Medical Sciences, Tehran, Iran

Payam Azadeh

Department of Radiotherapy and Oncology, Shaheed Beheshti University of Medical Sciences, Tehran, Iran

Abdollah Fazlalizadeh

Department of Radiotherapy and Oncology, Shaheed Beheshti University of Medical Sciences, Tehran, Iran